《瑞士罗氏公司(ROCHE GROUP)2022年年度报告(英文版)(220页).pdf》由会员分享,可在线阅读,更多相关《瑞士罗氏公司(ROCHE GROUP)2022年年度报告(英文版)(220页).pdf(220页珍藏版)》请在三个皮匠报告上搜索。
1、Annual Report Why is access tohealthcare soimportant?Life-changing innovation is only meaningful if it reaches those who need it.We put access at the core of our business and consider it a key part of our commitment toimproving patient outcomes.Our combined strengths indiagnostics and pharmaceutical
2、s position us to play adecisive role along the patients journey.We partner withstakeholders to address the root causes at global,country and community levels that prevent access to innovative healthcare,no matter where people live.Shareholder letters 4Business performance 18Reporting and strategy 28
3、 Diagnostics 38 Pharmaceuticals 54 Personalised healthcare 70 Access to healthcare 84 People and culture 98 Environment 114 Community engagement 130 Business ethics 144 Corporate Governance 158 Remuneration Report more than 125 years,Roche has worked to improve thehealth of countless people all over
4、 the world.Withthetrust of our shareholders and guided by scientificprogress,we will continue to identify and seizeopportunities well into the future.Letters to shareholdersIn his final letter to shareholders,Christoph Franz reflects onthe companys performance in 2022 and the countless collaboration
5、s we have with partners around the world toincrease access to healthcare for everyone.Chairman Basel,SwitzerlandDr Christoph FranzFor the last time as CEO,Severin Schwan shares his thoughts on the progress we have made for patients and society and our advances in digital healthcare.CEO Roche Group B
6、asel,SwitzerlandDr Severin SchwanLetters to shareholders|Roche 7Dr Christoph Franz8Dear ShareholdersYour company achieved good results even in last years challenging environment.Sales increased by 2%*and net income amounted to 13.5billionSwissfrancs.The Board of Directors proposes at the Annual Gene
7、ral Meeting that the dividend be increased by 2%to 9.50Swiss francs per share and non-voting equity security,the36thincrease in succession.The challenges of the past year have been manifold.In particular,the war in Ukraine has brought unimaginable suffering to millions of people.It is having a massi
8、ve impact on the economy.At the same time,people around the world are still preoccupied with the consequences of the COVID-19 pandemic.In connection with the war in Ukraine,I was able to experience in a particularly impressive way how our employees are fully committed to providing patients with medi
9、cines and diagnostic tests.I am deeply grateful for the incredible helpfulness and initiative of our employees across borders.Currently,Roche has a total number of 87 new compounds and 65 additional indications in clinical development or registration.And our Diagnostics Division is also flourishing
10、thanks to the continuous development ofnew,innovative instruments and tests.That is whyI am very confident about the future of Roche.For our innovations to reach people,we need to work with our healthcare partners within each country.Roche is engaged in hundreds of partnerships and collaborations ar
11、ound the worldtoimprove access to our medicines and diagnostics,and thereby improve peoples lives.An example of this is our partnership with Project ECHO,a non-profit organisation which uses video telementoring for medical education and care management.The project connects national centresof excelle
12、nce to remote and underserved areas,giving patients access to specialised care that they otherwise wouldnt receive.Good healthcare can be life-saving for patients and creates enormous value for society as a whole.Imagine what it means when a person with cancer is cured thanks to a timely,accurate di
13、agnosis andeffective treatment,and can continue to be around for their family as well as contributing to society and the economy.Early diagnosis can even prevent illness altogether and thus avoid costly hospital stays.I hope that access to modern and effective healthcare will one day be possible eve
14、rywhere in the world.Roche is making a significant contributionhere.This is my final letter to you,esteemed shareholders of Roche.After twelve years on the Board of Directors,including nine as Chairman,I have decided not to stand for re-election at the next General Meeting in 2023.With Severin Schwa
15、n as the designated new Chairman of the Board of Directors and Thomas Schinecker as the new CEO,Roche is being led into the future by a strong and highly experienced team.*Unless otherwise stated,all growth rates and comparisons to the previous year are at constant exchange rates(CER;average rates 2
16、021)and all total figures quoted are reported in CHF.Chairmans shareholder letter|Roche 9“With Severin Schwan and Thomas Schinecker,Roche is being led into the future by a strong and highly experienced team.”I would like to thank Severin Schwan most sincerelyfor his outstanding achievements as CEO o
17、f Roche over the last 15 years,as well as for our always trusting and respectful cooperation.SeverinSchwan has contributed decisively to the major success of your company.I would particularly like tohighlight the integration of Genentech,a milestone in the development of Roche.Equally noteworthy is
18、the fact that our pharmaceuticals business has more than compensated for the loss of patent protectionfor our top-selling medicines thanks to the introduction of new,innovative products inrecent years.Finally,I am delighted that we are able to further strengthen the Board of Directors of Roche with
19、two key personalities:the Board of Directors will propose Mark Schneider,CEO of Nestl,and AkikoIwasaki,Professor of Immunobiology and Molecular,Cellular and Developmental Biology at Yale University and a researcher at theHowardHughes Medical Institute,at the 2023 Annual General Meeting for election
20、as newBoardmembers.It has been a great honour for me to work for this unique and excellent company.Roches success is due in particular to the fact that the company has been owned by the founders descendants for over 125years.The owner families long-term orientation enables the leadership of Roche to
21、 make the right decisions,so that the company can continue to make major contributions to peoples health for many years ahead.I therefore thank the owner families for their great support.I would also like in particular to thank all Roche employees for the significant medical advances we have achieve
22、d together.And thank you very much,dearshareholders,for your trust.Dr Christoph FranzChairman10Roche Board of Directors on 31 December 2022 Bernard Poussot(1952),C,E,G Dr Jrg Duschmal(1984),representative of the shareholder group with pooled voting rights,B,E,G Dr Christoph Franz(1960),Chairman,C,D*
23、,E,G Andr Hoffmann(1958),Vice-Chairman,representative of the shareholder group with pooled voting rights,A*,C*,D,E,G Dr Severin Schwan(1967),F Dr Claudia Suessmuth Dyckerhoff(1967),A,B,E,GDr Patrick Frost(1968),B*,C,E,G Anita Hauser(1969),A,E,G Prof.Dr Richard P.Lifton(1953),C,E,G Dr Jemilah Mahmood
24、(1959),A,E,GA Corporate Governance and Sustainability Committee|B Audit Committee|C Remuneration Committee|D Chairmans/Nomination Committee E Non-executive director|F Executive director|G Independent member of the Board of Directors|*Committee chairpersonChairmans shareholder letter|Roche 11Thank yo
25、u very much,Christoph Franz!At this years General Meeting,Christoph Franzs many years of work at the head of our company will come to an end.After twelveyears on the Board of Directors and nineyears as its Chairman,Christoph Franz has decided not to stand for re-election.There is no doubt that,throu
26、ghout his tenure,our outgoing Chairman has strongly influenced Roches strategic development.He has made a considerable personal contribution to the success of our company.Although he joined Roche from elsewhere in 2011,Christoph Franz was able to make valuable contributions to the Board of Directors
27、 from the outset.This was undoubtedly a result of his many years of experience in international companies.Together with the Board of Directors and the Executive Committee,he did not simply manage problems,but tackled them promptly and provided constructive solutions.In so doing,he confidently and su
28、ccessfully steered our company through challenging times with great dedication.Examples I would like to mention here include Roches contribution during the pandemic and handling thepatent expiry of our three most widely used cancer medicines.In addition,Christoph Franz made an important contribution
29、 to expanding Roches strategic flexibility by repurchasing the Roche shares held by Novartis.Since he took on the top role at Roche,digitalisation in the healthcare sector has also accelerated and alongside it,a far-reaching transformation of our company.Roche today is clearly different from Roche a
30、 decade ago.Giving people worldwide access to our medicines and diagnostics has always been one of ChristophFranzs particular concerns.During his travels to Roche subsidiaries in Africa,Asia and South America,he therefore always took the time to visit local hospitals and to talk to doctors,local nur
31、sing staff and patients.Together with local government representatives,he effected a remarkable number of agreements between Rocheand governments around the world,with theaim of working together to improve local healthcare systems.I have personally always appreciated that ChristophFranz,with his wea
32、lth of entrepreneurial experience and wide-ranging knowledge,has advocated not only obvious solutions but also andin particular some challenging choices that were,and still are,key tosafeguarding Rochesfuture.On behalf of the entire Board of Directors,theOeri,Hoffmann and Duschmal families,and mysel
33、f,I would like to sincerely thank our Chairman for all of this.Andr Hoffmann Vice-Chairman of the Board of Directors12Andr HoffmannLetter of the Vice-Chairman|Roche 13Dr Severin Schwan14Dear ShareholdersOverall,we achieved good results last year.This is primarily due to the continued strong demand f
34、or routine diagnostics and our newer medicines to treat serious diseases such as multiple sclerosis,haemophilia,severe eye diseases,spinal muscular atrophy and cancer.The development and delivery of pioneering medicines and diagnostics is at the heart of our mission.Innovations from Roche improve th
35、e lives of people worldwide:in 2022,29 billion tests were performed with our diagnostic products,delivering crucial information on disease prevention,diagnosis and treatment.And millions of patients were treated with Roche medicines.I am particularly pleased with our recent successes in ophthalmolog
36、y:Vabysmo is a novel treatment for certain severe eye diseases.Launched at the beginning of 2022,a large number of patients already have access to this innovative eye medicine.Vabysmo became one of our most important growth drivers injust a few months.Last year,we were also able to provide patients
37、with two important medicines for blood cancer.Lunsumio gives hope to people with a certain form of follicular lymphoma.This blood cancer develops slowly,but has been incurable up to now.Our new immunotherapy activates the bodys own immune system a promising new approach to blood cancer.Polivy signif
38、icantly improves the chances of curing a particularly aggressive form of blood cancer.For two decades,research in this area made little progress,so this is a real medical breakthrough.Another highlight:our cancer immunotherapy Tecentriq has now also been approved in Europe and other countries for th
39、e treatment of early-stage lung cancer.For many people this raises theprospect of a cure.Innovative research and development does not only carry opportunities,but also risks.In addition to many successes,we also experienced setbacks last year first and foremost the disappointing study data on ganten
40、erumab in the treatment of Alzheimers disease.Such setbacks are not a reasonto give up,but part of the often long,iterative research and development processes in our industry.We learn from the study data and implement these lessons in the next study.Roche has other molecules against Alzheimers in de
41、velopment.We will continue to have the entrepreneurial courage to invest in particularly high-risk research areas such as Alzheimers and hope that we will ultimately achieve a breakthrough for patients.Innovative diagnostic solutions enable early and reliable decision-making,whether in infectious di
42、seases,cancer or other diseases.With the PCR test kits developed in record time for the detection of the mpox virus,we have proven once again after COVID-19 that we are able to respond quickly to new public health threats.Certain human papillomaviruses(HPV)may causecervical cancer.Our new HPV self-s
43、ampling solutionoffers women the possibility to take the cervical samples needed for HPV testing Shareholder letter CEO Roche Group|Roche 15Roche Corporate Executive Committee on 31 December 2022 Dr Alan Hippe(1967),Chief Financial and Information OfficerClaudia Bckstiegel*(1964),General CounselDr A
44、viv Regev*(1971),Head Genentech Research and Early Development(gRED)Prof.Dr Hans Clevers*(1957),Head Roche Pharma Research and Early Development(pRED)DrSeverin Schwan(1967),CEO Roche GroupCristina A.Wilbur(1967),Chief People OfficerBill Anderson(1966),CEO Roche PharmaceuticalsBarbara Schdler*(1962),
45、Head Group CommunicationsDr James H.Sabry*(1958),Global Head Pharma PartneringDr Thomas Schinecker(1975),CEO Roche Diagnostics*Member of the Enlarged Corporate Executive Committee16“I am particularly pleased that we brought twonew medicines to patients:Vabysmo for certain severe eye diseases and Lun
46、sumio for acurrently incurable form of blood cancer.”themselves while at a healthcare facility.This solution can help breakdown barriers to screening for cervical cancer.The new HCV Duo assay can also help prevent cancer,as well as other diseases caused by hepatitisC.Theassay provides both antigen a
47、ndantibody results in one test,thus helping diagnose hepatitisCfaster.We have also further expanded our digital healthbusiness.For example,our new digital solution for pathology now delivers high-resolution digital images of tissue samples even faster.The evaluation is not carried out using a micros
48、cope,butelectronically.Artificial intelligence now often sees more than the human eye.This makes it easier to diagnose cancer and enables more targeted andeffective treatment for the patient concerned.In fragmented healthcare systems,medical knowledge is often untapped today because of inadequate di
49、gitalisation.Thats where our cloud-based platform cobas infinity edge comes into play.It enablesnursing staff and doctors to securely share patient data from multiple sources and brings together a range of health data,such aselectronic patient records,third-party apps,andpoint-of-careservices.The di
50、gital transformation is bringing about huge advances for patients.With pharmaceuticals,diagnostics and digital solutions under one roof,Roche is very well positioned to perform pioneering work in this field and not for the first time in our more than 125-year history.I would like to thank all our em
51、ployees for their tireless commitment in this challenging year.And I would like to thank our Chairman,Christoph Franz,for his many years of confidence-inspiring work.He has always been passionate about ensuring that our products and solutions reach the people who desperately need them no matter wher
52、e they live.Thomas Schinecker will take over my role as CEO from mid-March.I would like to thank him for his outstanding work as Head of the Diagnostics Division and look forward to continue working withhim.Thank you,dear shareholders,for your trust in ourcompany.Dr Severin SchwanCEO Roche GroupShar
53、eholder letter CEO Roche Group|Roche 1718Business performanceWe achieved good results in 2022.As expected,the demand for COVID-19 products declined.Thediagnostics base business and our newer medicines continued their strong growth.Material topic Long-term mindsetUN SDGsBusiness performance|Roche 196
54、3,281+2.2%62,801+9.3%9.50 9.30 45,551+2.1%45,041+3.1%17,730+2.5%17,760+29.5%22,173+3.4%21,897+4.1%14,053+2.7%13,708+14.3%Key figures 2022Group sales2022 2021Dividend2022 2021Pharmaceuticals sales2022 2021Diagnostics sales2022 2021Core operating profit2022 2021R&D core investments2022 2021CHF million
55、sCHF*Unless otherwise stated,all growth rates and comparisons to the previous year are at constant exchange rates(CER;average rates 2021)and all total figures quoted are reported in CHF.*20Employees*by Operating Divisional GroupCorporate and other9,037Pharmaceuticals46,793Chugai7,822Diagnostics39,96
56、114.2 million patients treated with Roche medicines 33research and development sites in Pharmaceuticals and Diagnostics worldwide 20 manufacturing sites in Pharmaceuticalsand Diagnostics worldwide32 Roche medicines on the WHO Model List of Essential Medicines*Number of employees expressed in full-ti
57、me equivalents,on 31.12.2022Business performance|Roche 21*Unless otherwise stated,all growth rates and comparisons to the previous year are at constant exchange rates(CER;average rates 2021)and all total figures quoted are reported in CHF.1 The IFRS result includes non-core items such as global rest
58、ructuring plans and amortisation and impairment of goodwill and intangible assets.In 2022,Roche sales rose 2%*(+1%in CHF)to CHF63.3billion.Core operating profit increased by 3%(+1%in CHF),reflecting the good underlying business performance.IFRS net income1 was CHF 13.5 billion,decreasing by 6%compar
59、ed to 2021.This was due to higher impairments of intangible assets and higher interest costs and income taxes.Core earnings per share grew 5%(+2%in CHF).This includes the positive impact of the repurchase of Roche shares held by Novartis.Pharmaceuticals Division sales increased by 2%to CHF 45.6 bill
60、ion.Newer medicines to treat severe diseases continued their strong growth.Vabysmo,an eye medicine launched at the beginning of 2022,is already one of the top five growth drivers.This medicine,together with Ocrevus(multiple sclerosis),Hemlibra(haemophilia),Evrysdi(spinal muscular atrophy)and Tecentr
61、iq(cancer),generated additional sales totalling CHF 3.2 billion.Sales of COVID-19 medicines were generally lower,with a decline of roughly CHF0.5billion.The decrease in sales of Actemra/RoActemra for severeCOVID-19 pneumonia was only partially madeup by the sales growth of Ronapreve for high-risk pa
62、tients in Japan.Roche GroupAs expected,the impact of biosimilars on the sales of the cancer medicines MabThera/Rituxan,Herceptin and Avastin continued to slow down,which resulted in a combined CHF 1.9 billion reduction in sales.The Diagnostics Division increased its sales by 3%to CHF17.7billion.The
63、divisions base business up 7%achieved good results over the year and across all regions,with growth mainly driven by immunodiagnostic products.Our broad portfolio of COVID-19 tests generated sales totalling CHF4.1billion in 2022 compared toCHF4.7billion in 2021.Outlook for 2023 Due to the sharp decl
64、ine in sales of COVID-19 products of roughly CHF 5 billion,Roche expects a decrease in Group sales in the low single digit range(at constant exchange rates).Excluding this COVID-19 sales decline,Roche anticipates solid underlying sales growth in both divisions.Core earnings per share are targeted to
65、 develop broadly in line with sales decline(at constant exchange rates).Roche expects to further increase its dividend in Swiss francs.22Pharmaceuticals Division45,551+2%Diagnostics Division17,730+3%Roche Group 63,281+2%Sales in 2022(CHF millions)Business performance|Roche 23Diagnostics Diagnostics
66、Division sales grew by 3%to CHF17.7billion.The divisions base business up7%achieved good results over the year and across all regions.Growth was mainly driven by immunodiagnostic products.Our broad portfolio of COVID-19 tests generated sales totalling CHF4.1billion in 2022 compared toCHF4.7billion i
67、n 2021.Sales in the Asia-Pacific and North America regions increased by 23%and 13%,respectively.The 16%drop in sales in the Europe,Middle East and Africa(EMEA)region is primarily due to the reduced demand for COVID-19 testing.Core Lab sales increased by 6%.Immunoassays,such as cardiac and oncology t
68、ests,and clinical chemistry products were the main growth drivers.Sales grew across all regions,most strongly in Asia-Pacific,EMEA and Latin America.This customer area focuses on central labs and provides diagnostics solutions in the areas of immunoassays,clinical chemistry andcustombiotech.Point of
69、 Care sales grew by 17%.The SARS-CoV-2 Rapid Antigen test continued to be the main growth driver.Demand for the cobas SARS-CoV-2&Influenza A/B assays also increased.The largest contribution came from the Asia-Pacific and NorthAmerica regions.This customer area provides diagnostics solutions immediat
70、ely at the point of care such as in emergency rooms,medical practices and directly with patients;it includes SARS-CoV-2 rapid tests and blood gas and electrolyte tests.Molecular Lab sales decreased by 15%due to lower COVID-19-related sales in the North America and EMEA regions.This was partly offset
71、 by growthin the base business across the portfolio.This customer area focuses on molecular labs and provides diagnostics solutions for pathogen detection and monitoring,donor screening,sexual health and genomics.Diabetes Care sales decreased by 2%due to the base effect of the resolution of a rebate
72、 dispute in 2021.Excluding this effect,sales remained stable.The continued contraction of the blood glucose monitoring market,in particular in the United States and Europe,was offset by a higher demand in emerging markets.This customer area focuses on integrated personalised diabetes management for
73、people withdiabetes and healthcare professionals.Pathology Lab sales increased by 11%due to growth in the advanced staining and the companiondiagnostics businesses.Sales grewacross allregions.This customer area focuses on pathology labs andprovides diagnostics solutions for tissue biopsies and compa
74、nion diagnostics.These targeted diagnostics support the specific therapydecisions for each patient.24Core Lab Point of Care Molecular Lab Diabetes Care Pathology Lab7,775+6%3,589+17%3,450 15%1,598 2%1,318+11%Sales by customer area in 2022CHF millionsBusiness performance|Roche 25PharmaceuticalsPharma
75、ceuticals Division sales increased by 2%to CHF45.6billion.Newer medicines to treat severe diseases continued their strong growth.Sales in the United States decreased slightly by 1%.The sales growth of the newer medicines Ocrevus,Vabysmo,Hemlibra and Tecentriq partially compensated for the sales decl
76、ine of Actemra/RoActemra for COVID-19 and medicines whose patents have expired.In Europe,sales were also slightly down by 2%,mainly due to lower sales of the COVID-19 medicine Ronapreve.Excluding this base effect,sales in Europe increased by 6%,as the newer medicines more than offset the impact of b
77、iosimilars.Sales in Japan increased by a substantial 26%.The key factors were supplies of Ronapreve to the government,followed by sales growth of Evrysdi,Polivy,Hemlibra and Enspryng,which more than offset the impact of biosimilars and government price cuts.Sales in the International region grew by
78、1%.In China,sales decreased by 7%due to biosimilars,lower sales of Rocephin and local COVID-19 measures.Excluding China,sales in the region increased by 6%,mainly as a result of a higher demand for Perjeta,Hemlibra,Ocrevus and Kadcyla.Ocrevus(CHF 6.0 billion,+17%).Relapsing and primary progressive f
79、orms of multiple sclerosis;two-hour-only infusion.The demand for Ocrevus in both indications remained strong in the United States.In Europe and in the International region,themedicine continued to show a high uptake.Perjeta(CHF4.1billion,+5%).HER2-positive breast cancer.Sales increased mostly due to
80、 the continuing high demand in the International region,mainly in China.Hemlibra(CHF 3.8 billion,+27%).HaemophiliaA with and without factor VIII inhibitors;only prophylactic treatment that can be administered subcutaneously once weekly,every two or every four weeks.Sales continued to show an impress
81、ive uptake,especially in the United States and Europe.Sales in the International region grew across all major markets.Tecentriq(CHF 3.7 billion,+14%).Cancer immunotherapy(either alone or in combinations)for various types of cancer,e.g.lung,bladder,breast and liver cancer.Sales increased mostly due t
82、o the higher demand in the United States and Europe.Sales in Japan decreased,primarily due to governmental price cuts.Actemra/RoActemra(CHF 2.7 billion,22%).Rheumatoid arthritis,forms of juvenile idiopathic arthritis,giant cell arteritis,CAR T-cell-induced severe or life-threatening cytokine release
83、 syndrome and COVID-19.Sales decreased,mainly in the United States and the International region,driven by lower demand for patients with severe COVID-19 pneumonia.26Top-selling pharmaceuticals in 20226,036+17%4,087+5%3,823+27%3,717+14%2,701 22%2,208+9%2,142 19%2,122 28%2,080+7%2,075 20%Ocrevus Neuro
84、science Perjeta Oncology Hemlibra Haemophilia Tecentriq Oncology Actemra/RoActemra Immunology Xolair Immunology Herceptin Oncology Avastin Oncology Kadcyla Oncology MabThera/Rituxan Oncology/ImmunologyCHF millionsBusiness performance|Roche 2728Roche is committed to transparent reporting and we endea
85、vour to drive our economic,social and environmental performance with the same diligence as our financial performance.It is why sustainability is built into our business strategy and part of everyones job at Roche.We focus on finding new medicines and diagnostics and on establishing data-based insigh
86、ts that evolve the practice of medicine andhelp patients live longer,better lives.Reporting and strategyReporting and strategy|Roche 29Report 2022:| management: Performance Indicators: reviewed externally when appropriate.Riskmanagement is embedded at all levels of the Roche Group.Our Pharmaceutical
87、s and Diagnostics Divisions and global functions conduct a formal riskand opportunity assessment at least once a year and must develop response plans for their mostmaterial risks and opportunities.Read more in Corporate Governance on page158.We also identify long-term business sustainability trends
88、with associated risks and opportunities on an annual basis and integrate these into our existing Group Risk Management Process.Each year,ten emerging trends(including associated risks and opportunities)are identified from internal and external sources.Based on these findings,the Sustainability Steer
89、ing Committee prioritises and selects the top business sustainability trends.The two most important business sustainability trends for 2022 are the following:i)Future of work and ii)Mistrust and scepticism in science.These two trends,as well asone of their associated opportunities and risks,are desc
90、ribed on page 31.UN Sustainable Development GoalsWe support the United Nations Sustainable Development Goals(SDGs)within the sphere of our corporate business strategy.We contribute to a number of the SDGs,but our greatest contribution is to SDG3,Good Health and Well-Being.This goal is closely connec
91、ted with the achievement of universal health coverage,which goes hand in hand with better access to quality essential medicines and diagnostics.This is fully aligned with our vision to improve and save lives.Since 2016,the SDGs have been an integral part of our annual reporting.Roche is committed to
92、 transparent reporting and we endeavour to drive our economic,social and environmental performance with the same diligence as our financial performance.Reporting scope and boundariesOur financial and non-financial reporting consists of the Annual Report,the Finance Report and the online report.It co
93、ntains the annual financial statements,consolidated financial statements and non-financial performance indicators.It covers all regions and divisions of the Roche Group from 1January to 31 December 2022.The financial reporting scope is defined and outlined in our Finance Report,and there have been n
94、o significant changes in scope in 2022 compared to 2021.GRI Standards and materialityWe have been a member of the Global Reporting Initiative(GRI)community since 2007,have followed the GRI G4 guidelines since 2014 and have transitioned to reporting with reference to the 2016 GRI Standards.By using t
95、he GRI Standards,we disclose the most critical impacts of our activities on the environment,society and the economy.Risk managementOur Risk Management Policy sets out Roches approach to identifying,analysing,managing and reporting internal and external risks and opportunities.A consolidated Group Ri
96、sk Report,which covers all material risks and opportunities,is discussed annually with the Corporate Executive Committee and reviewed by the Board of Directors.The effectiveness of the Group Risk Management Process is regularly monitored by the Group Risk Advisory team and the overall process review
97、ed by the Audit Committee of the Board of Directors,Our reporting approach30Business sustainability trendsFuture of work Trend descriptor:New,diverse and complex working models(remote,hybrid)lead to an increasingly fluid workspace and workforce,which requires an agile workforce management to avoid n
98、egative impacts as well as to leverage positive impacts on talent attraction,retention and engagement,especially in a highly innovation-dependent sector.Opportunity:Roche can be positioned as an attractive employer through our flexible ways of working.Risk:Disconnection within the company and increa
99、sed silo thinking canreduce innovation and drive duplication.Mistrust and scepticism in science Trend descriptor:A growing educational gap and populism with increasing spread of fake news(intended or unintended)are leading to mistrust and scepticism in science,medical therapies,pharmaceutical indust
100、ry andinstitutions.Opportunity:A competitive advantage can be created for Roche through the strengthening of relationships with governments,patient organisations,payers and doctors(e.g.sharing information,providing education).Risk:Patients and society are not benefitting from scientific advancements
101、 and resulting medicines due to lack of awareness or saturation with falseinformation.The full list of business sustainability trends and their associated risks and opportunities can be found on our risk management website(link on the previous page).Examples of our contribution to the UN goals are l
102、isted on our UN SDG webpage(see link on page32)and are mapped to our material topics as featured on page 33.As a signatory of the UN Global Compact(UNGC),we commit to integrate the universal principles in the areas of human rights,labour,environment and anti-corruption intoour business strategy,cult
103、ure and daily operations and to report on the results achieved each year.We published our first Communication on Progress(CoP)in the first quarter of 2022 and willsubmit oursecond CoP in the first quarter of2023.External assuranceSome selected key figures of our non-financial reporting for the year
104、ended 31December2022 have been subject to limited assurance procedures performed by PricewaterhouseCoopers AG(PwC),an independent third-party assurance provider.PwC provides limited assurance on selected key figures in the areas of:i)safety,security,health and environmental protection,ii)people and
105、culture and iii)grants,donations,and sponsorships.These key figures are disclosed in the Annual report and/or on the non-financial reporting webpage,together with the related PwC limited assurance report,and are defined in our Non-Financial Reporting Metrics Guidelines Basisfor Preparation.See Indep
106、endent Assurance Report on page210.Our reporting approach|Roche 31EnvironmentThe respect for a healthy planet and for the environment has always been a priority of our founding families and the company.We are committed to halving the environmental impact of our operations and products from 2019 to 2
107、029.And we aim to reduce our own greenhouse gas emissions to absolute zero by 2050,while partnering with our suppliers to reduce their emissions for our mutual benefit.EconomyOur business must meet the needs of patients andcontinue creating quality jobs that provide people and their families with se
108、cure livelihoods,while earning competitive returns for our investors.We do this by promoting innovation and by translating science into pioneering medicines and diagnostics that help patients live longer,better andmore productive lives enabling them to support themselves and contribute to their loca
109、leconomies.As described in our strategy,our set-up is designedfor innovation.Our autonomous research and development centres and alliances with more than 250external partners foster a diversity of scientific approaches and agility.Roche operates inover 150countries where our local teams implement ou
110、r strategy.We measure our performance and report to all our stakeholders theprogress towardsthe goals we have set ourselves.Our purpose is Doing now what patients need next.How we identify and meet those needs whatwe do every day must be sustainable if we are to succeed.It is why sustainability is b
111、uilt into our business strategy and part of everyones job atRoche.Our approach is holistic and integrates the three dimensions of sustainability:Society how we contribute to a better tomorrowfor all Environment how we minimise our impact onnature Economy how we invest in medical advances,create jobs
112、 and ensure livelihoodsWhat does this mean for each of us at Roche,everyday?SocietyWe contribute to a better society by enabling the righttreatment for the right patient at the right time for the right value.We do this by developing new medicines and ways of diagnosing disease and gaininginsights fr
113、om data.Our commitment to expandaccess to these innovations will help more patients live longer,better lives.And with this comes a deep respect for the human rights of everyone we reach,especially patients,business partners,suppliers,local communities and,of course,our colleagues around the world.It
114、 is why we emphasise employee safety,health and development while promoting diversity and inclusion,integrity,mutual respect and equal opportunities for all.Materiality and impactSustainability: engagement: performance indicators: contribution tothe UN SDGs: to healthcareAffordability of healthcareA
115、vailability of healthcareSustainable healthcare systemsDigitalisationCybersecurityData privacyPersonalised healthcareReal-world dataScience and innovationPatient centricityPreparedness for ageing societyR&D efficiencyProduct quality and safetyProduct safetyProduct qualityOur 19 material topicsEthics
116、 and complianceComplianceEthics and transparencyHuman rightsEmployee engagementOrganisational agilityPreparedness for ageing societyTalent attraction and retentionEnergy efficiencyEnergy efficiencyLong-term mindsetLong-term mindsetMateriality and impact|Roche 33Materiality assessment and stakeholder
117、 engagementEngaging with our stakeholders is essential to build trust and an understanding of their expectations.By embedding their feedback in our strategy and our daily business,we are able to jointly address our common issues and develop long-term solutions.In order to identify the topics that ar
118、e particularly relevant to Roche,our stakeholders and society at large and to deliver lasting shared value,we conducted an in-depth materiality assessment at corporate level among our key stakeholders in 2018/2019.Ourapproach to materiality assessment is integrated building on our Group Risk Managem
119、ent Process and inclusive,being designed collaboratively with colleagues across multiple functions.We gathered insights from a broad range of internal and external stakeholders to identify the most important and pressing issues that Roche should address in the next three to five years.We identified
120、19material topics,clustered in eight main categories,that stood out as highly relevant to us and to our key stakeholders.To properly address these topics,we have then aligned them with our current goals and are measuring performance through our defined set of indicators.Additionally,we are currently
121、 conducting an in-depth materiality assessment at Group level in order to update the listof material topics we identified in 2018/2019.Impact-driven sustainability initiativesIn order to maximise our impact within and beyond the healthcare industry,we have joined two notablesustainability initiative
122、s,namely the Sustainable Market Initiative and the Value Balancing Alliance.The Sustainable Market Initiative(SMI)is a multi-stakeholder initiative which aims to lead the transition to a sustainable future by convening public-and private-sector leaders to align economicvalue with social and environm
123、ental sustainability.Part of the SMI commitments are the climate actions in line with the Science Based Targets Initiative(SBTi).The Value Balancing Alliance(VBA)is an initiative in which an alliance of multinational corporations develop and pilot,alongside leading academic institutions,astandardise
124、d methodology to ensure greater sustainability and transparency.This is done through greater disclosure of environmental,social and economic impact.We alsosupport the#MakeItMandatory campaign,which is calling formandatory requirements for all large businessesand financialinstitutions toassess and di
125、sclose theirimpacts and dependenciesonbiodiversity by2030.34 14.2 million patients treated with Rochemedicines 29 billion tests conducted with Roche Diagnosticsproducts 87 new molecular entities in clinicaldevelopment 37%of women in executive positionsSociety How we contribute to a better tomorrow f
126、or allOur impactOur 2022 performanceOur material topics*Supporting UN SDGs 32%decrease in our environmental impact peremployee since 2019 81%of our electricity coming from sustainablesources 29%decrease in greenhouse gas emissions since2019Environment How we minimise our impactonnatureEconomy How we
127、 invest in medical advances,create jobs and ensure livelihoods 22.21%of sales invested in R&D 103,613 employees Long-term mindset Energy efficiency Access to healthcare Product quality and safety Digitalisation Science and innovation Ethics and compliance Employee engagementOur impact*Clustered mate
128、rial topics for details see: and impact|Roche 35We focus on finding new medicines and diagnostics and on establishing data-based insights that evolve the practice of medicine and that help patients live longer,better lives.Our business environment is undergoing tremendouschange.We are facing new cha
129、llenges due to the complexity of care and increasing pressure on healthcare budgets.At the same time,we see new opportunities arising from major advances in life sciences and from digitalisation inhealthcare.In these turbulent times,we are guided by our common purpose:Doing now what patients need ne
130、xt.Our company has been bringing novel diagnostics and treatments to patients for125years.Patients are and will remain at thecore ofwhat we do.They are the reason wecome toworkevery day.What we do We focus on our vision of fitting treatments to patients:providing the right therapy for the right pati
131、ent to ensure the best response at the right time for the right value.Our approach combines our rich expertise in pharmaceuticals and diagnostics with expanded data science capabilities to drive more effective and efficient research and to enablebetter therapeutic decisions for patients.Our pursuit
132、of excellence in science rests on four key elements:an exceptionally broad and deep understanding of disease biology;the seamless integration of our capabilities in pharmaceuticals and diagnostics;a diversity of approaches to maximise innovation;and a long-term orientation.Working in partnership wit
133、h third parties,we offer integrated solutions with improved medical,healthand economic benefits.Wework with manydifferent stakeholders in the healthcare ecosystem to broaden access to our offerings forpeople who need them and,ultimately,toprovide a seamless patient journey.We will continueto concent
134、rate our energies on prescription medicines,in vitro diagnostics and increasingly data and insights,rather than diversifyinto other sectors likegenerics,biosimilarsor over-the-counter medicines.Our delivery is to create value for all our stakeholders:being a partner of choice;bringing significant me
135、dical benefit for patients,doctors and payers;offering a great place to work for employees;delivering a sustainable positive contribution to society;and earning competitive returns for our investors.How we do it Ultimately,delivering on our commitments takes people with integrity,courage and a passi
136、on formaking a difference for patients.Our people areproud to say:We are Roche.Our leadership inspires outcomes that matter by embracing diversity and inclusion.Different backgrounds,perspectives and experiences,acrossthe entire organisation,foster innovative solutions for the benefit of patients.Ou
137、r ways of working enable agile and networked responses to the ever-increasing pace of change by balancing theneeds for stability,speed and flexibility.Our set-up is designed for innovation.Our autonomous research and development centres and alliances with more than 250external partners foster a dive
138、rsity of scientific approaches and agility.Our global geographical scale and reach enables us to attract talent in the leading global science clusters and to quickly bring our solutions topeople who need them.Our strategy36Our focusFitting treatments to patientsOur leadershipInspiring outcomes that
139、matterOur distinctiveness Excellence in scienceOur set-upBuilt for innovationOur deliveryValue for all stakeholdersOur ways of workingAgile and networkedHow we do itWhat we doOur strategy|Roche 3738DiagnosticsWe are committed to advancing diagnostic solutions that can support healthcare professional
140、s in making critical decisions for their patients health and also improving the way these essential tools are integrated into health systems around the world.Hiros work at Roche enables him to follow his passion of developing diagnostics to address unmet patient needs.His many scientific breakthroug
141、hs have already impacted the lives of millions of patients around the world.Senior Scientific Fellow Tucson,USAHiro NittaDr Jamil partners with stakeholders across the healthcare system to increase access to care and diagnostics in Pakistan.Her efforts have led to theprovision of patient-centric int
142、egrated care.Professor of Medicine and Infectious Diseases Karachi,PakistanDr Bushra Jamil Diagnostics|Roche 41Hiro Nitta42A steadfast commitment to improving access tovital diagnosticsHiro Nittas dedication to continually improve accessfor patients began when he was just a teenager.As an 18-year-ol
143、d college student in Japan,Hiro developed a passion for all aspects of histology the study of tissues.He spent his days dissecting samples,analysing data and eventually publishing the findings that now serve as the foundation for scientists involved in developing state-of-the-art tissue-based diagno
144、stics.Those early academic days were only the beginning of Hiros decades-long commitment to developing even more precise diagnostics for HER2-positive breast cancer patients.Its a journey Hiro considers to be his lifes work.In 2000,Hiro began working for Ventana Medical Systems,which was acquired by
145、 Roche in 2008.Today,he is a Senior Scientific Fellow in Clinical Development and Medical Affairs at the Roche Diagnostics Solutions campus in Tucson,Arizona.And he has no plans of slowing down any time soon.As Hiro explains,“We have somuch moreto do for patients.Theres no time towaste.”What is HER2
146、?As many as 20%of the 2.3 million cases of breast cancer diagnosed globally each year are fuelled by the HER2 gene.1,2 Many HER2-positive patients can benefit from a specific targeted therapy.But determining which patients should receive the treatments initially required highly specialised technolog
147、y.“Some women didnt get the right treatment because of challenges with testing,”Hirosays.“I wasnt okay with that.”While working at Ventana,Hiro dedicated himself todeveloping a simpler test that could be conducted in any lab and could quickly and accurately diagnose HER2-positive patients,anywhere i
148、n the world.He succeeded.Just the beginning After the new diagnostic was launched,Hiros commitment only deepened.“Missing one patient who could be receiving life-saving therapy is one too many,”Hiro says.His new goal was to develop even more precise diagnostics.Hiros work at Roche enabled him to fol
149、low his passion of developing diagnostics to address unmet patient needs.He has created a next-generation HER2 test that can determine which specific type of cells are present in a tumour.That valuable insight is used to inform new therapy protocols and could eventually enable more HER2-positive pat
150、ients to experience better outcomes.Hiro has also discovered a previously unknown type of tumour cell structure and is working with other breast cancer researchers to investigate how this type of tumour responds to targeted therapy.At the same time,he is developing tests thatwill provide valuable in
151、formation that cannot be obtained through the diagnostics currently available.In 2022,Hiros research on the novel assay which evaluates both the HER2 gene and HER2 protein with a single tissue sample was presented at meetings of the United States and Canadian Academy of Pathology as well as the Euro
152、pean Society for Medical Oncology.Access has multiple elements For Hiro,improving access means that all cancer patients have the opportunity to be tested with the most innovative and accurate methods,and 1 Breast cancer fact sheet 2021,World Health Organization2 Recommendations for human epidermal g
153、rowth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update Journal of Clinical OncologyDiagnostics|Roche 43those results can then be used to select the treatment protocol that can most effectively saveore
154、xtendtheir lives.Hiro describes his commitment this way:“It shouldnt matter where someone lives or how much money they have.Everyone deserves accessto the best cancer diagnostic tools and therapies,so they can have more time with the people they love.To help make that goal a reality Iwill continue w
155、orking on developing better and more precise tissue-based cancer diagnostics foraslong as I can.”Inspiration,everywhere While Hiros accomplishments begin in his laboratory,he knows the impact of his work happensoutside those doors.Hiro can be found in cancer treatment facilities around the world,mee
156、ting with research collaborators.These visits provide the invaluable opportunity to connect withcancer patients and their family members.Evena casual conversation inthe lobby of a hospitalhelpsHiro maintain his focus on the ultimate beneficiaries of his work.By getting to know patients as people,he
157、can better understand their individual journeys,the challenges they face and their hopes for the future.“When we focus on patients,”Hiro explains,“we knowwhat wemust do.”Hiro has another unique perspective that inspires his work.In March of 2021,he experienced a dangerously severe COVID-19 infection
158、.At one point,he was not expected to survive.He considers his eventual recovery to be an invaluable second chance to continue his work and to do even more forpatients.Here is how Hiro explains the impact ofhis experience:“I understand now,more than ever,the fear and hope patients feel,and their worr
159、y over limited treatment options.I got a second chance to live.I believe I survived so I could work harder than ever to give cancer patients their second chance.That is what this experience has left me with,and what drives meto make a greater difference.”Hiro still needs to manage his life due to sy
160、mptoms of long COVID.This further reminds him of the needfor better testing and treatment choices for allpatients.A life in full As committed as Hiro is to his work,he does have interests outside of the lab.He is an award-winning magician and performs for children in hospital paediatric units.He als
161、o raises standard poodles,and shows them in competition.Add to that a love ofDisney and a talent for baking,and Hiro looks to be the very definition of a well-rounded individual with a passion-filled life.Hiros many scientific breakthroughs have already impacted the lives of millions of patients aro
162、und the world.His commitment to reaching even more people with the highly precise diagnostics that canlead to more effective treatments continues todrivehim,every day.“Everyone deserves access to the best cancer diagnostic tools and therapies,so they can have more time with the people they love.”44I
163、n his quest to continuously improve breast cancer diagnosis,HiroNitta spends his days investigating cancer cells.He is dedicated to ensuring patients have access to appropriate treatment options through improved understanding of cancerbiology.Diagnostics|Roche 45Enabling access to quality care and c
164、ritical diagnostics inPakistanGrowing up with a father as a physician,DrBushra Jamil was exposed to the practice of medicine from a young age.Reading his medical books as a child instilled a love of science and a drive to follow in her fathers footsteps.Despite being a female in a predominantly male
165、-dominated field,DrJamil studied various areas of medicine in both Pakistan and the United Kingdom,and is now a Professor of Medicine and Infectious Diseases at Aga Khan University Hospital(AKU)in Karachi,Pakistan,and also the President of the Medical Microbiology&Infectious Diseases Society of Paki
166、stan(MMIDSP).Diagnostics infrastructure is key A great deal of Dr Jamils work at both AKU and MMIDSP is focused on increasing access to quality healthcare in Pakistan.“The lack of an effective healthcare delivery system is a huge challenge in Pakistan,”says Dr Jamil.“Although it varies from province
167、 to province,the system is extremely fragmented and of poor quality.There is an urgent need to invest to close the gaps,particularly as it relates to accessing diagnostics services and adequately training healthcare professionals.”Unfortunately,the COVID-19 pandemic exacerbated these issues and brou
168、ght about the realisation that a robust diagnostics infrastructure,for COVID-19 and other infectious diseases,is absolutely essential.“Diseases are not being diagnosed at an early stage and when patients are eventually diagnosed,there is not always a defined path for them to take,especially if they
169、live in a rural area.Some patients will have to go to a private clinic if they need urgent treatment.”A move towards patient-centred care The lack of a patient-centred system is also a significant challenge that DrJamil sees as a critical gap.“If a patient requires a number of different tests,they a
170、re often sent to different clinics in different areas rather than having basic diagnostics available under one roof.This is incredibly inconvenient for patients and is something we needto address.”In 2021,Dr Jamil served as National Coordinator for the Global Fund to Fight AIDS,Tuberculosis and Mala
171、ria grants with the Ministry of Health in Islamabad.She procured the COVID-19 mitigation grant with a focus on strengthening health systems and ensuring provision of integrated careand critical diagnostics all under oneroof.“This is thetype of clinical service which is neededacross the country,”says
172、 DrJamil.“While COVID-19 servedasa catalyst for funding,we now have theability todiagnose other infectious diseases using the same equipment.Thisis the model that willtrulymove theneedle when it comes to patientcare.”Roche has been working with DrJamil to ensure thatdistrict level secondary care hos
173、pitals are equipped with the diagnostics systems needed to provide this one-stop-shop approach.“If we have the right equipment,we need to use it in the most effective and efficient way possible,”says DrJamil.“This will have a huge impact on case detection as well as follow-up treatment,not to mentio
174、n the factthat if its done easily and conveniently,the patient will greatly benefit.”46Dr Bushra JamilDiagnostics|Roche 47As an infectious disease expert,Dr Jamil knows the important role diagnostics play in the detection and treatment of diseases such as tuberculosis,HIV and malaria.Once critical d
175、iagnostics infrastructures are in place,they can dramatically change the quality and timeliness of care patients receive.48Education is key Another important component of increasing qualityof care for patients in Pakistan is properly training healthcare professionals on the principles of effective d
176、iagnostics and management of diseases.“When a workforce is inadequately trained,they tend to bypass essential steps and patients are treated based on previous experience rather than on accurate diagnostics,”says DrJamil.“This can be harmful to the patient because the treatment is not based on accura
177、te and timely diagnostics.This also has negative implications for the community and the country as a whole.”In 2022,Roche Diagnostics Pakistan partnered with Dr Jamil and the MMIDSP to increase advocacy around diagnostics and enable improved patient access in order to minimise the countrys disease i
178、mpact.This partnership will deliver continuing medical education opportunities for healthcare professionals and execute disease awareness and education campaigns to emphasise the significance of timely diagnosis and treatment for prevention andmanagement across a variety of disease areas.A look to t
179、he futureWhen asked what the future could look like for healthcare in Pakistan,DrJamils answer is clear:“Public-private partnerships are critical.We need to be able to bring diagnostics that are available,affordable,simple and fast into the publichealthcare system in an economical manner.We can then
180、 work together to train the workforce and build these diagnostics capabilities into our procedures for improved patient journeys.I am confident that implementing these changes can truly make a difference in the lives of the people ofPakistan.”“We need to be able to bring diagnostics that are availab
181、le,affordable,simple and fast intothe public healthcare system in aneconomical manner.”Diagnostics|Roche 49For our Diagnostics Division,2022 was marked by three key trends.First,global awareness of the value of diagnostics across every aspect of healthcare grew significantly.Our COVID-19 portfolio c
182、ontinued to expand to meet demands related to the diseases evolution.Second,we also saw measurable growth in our base business,such as tests for cancer,cardiovascular disease,infectious diseases and more.Third,we advanced our efforts to build a sustainable digital health business that will set usupf
183、or successin a more digitalised market.From preventative screening to follow-up careDiagnostics play an increasingly critical role across the entire patient journey.With early diagnosis,disease progression may be slowed or even stopped.Diagnostic testing can provide patients,families and healthcare
184、professionals with information that may lead to the best possible outcome.For healthcare systems,access to diagnostic information for managing diseases helpsavoid unnecessary service delivery,reduces overall cost of care,improves its effectiveness and,most importantly,contributes tosaving lives.As d
185、emonstrated by the COVID-19 pandemic,diagnostics and information solutions can make a major difference in a countrys ability to cope with infectious disease outbreaks and maintain health systems.Advanced diagnostic solutions support earlier decision-making,help reduce hospitalisation,enable targeted
186、 treatment strategies and improve patient management.Driving innovation through digitalisationWe have been building our division-wide digital foundation,strategy and portfolio,further advancing our ambition to establish a sustainable digital health business.In 2022,we unified our digital health port
187、folio under the navify brand,providing a range of next-generation softwaresolutions.Through our Digital Pathology portfolio,we are transforming pathology.The VENTANA DP600 high-capacity slide scanner creates high-resolution digital images of stained tissue samples to help diagnose cancer and determi
188、ne a patients treatment.The Digital Pathology Open Environment allows software developers to easily integrate theirimage analysis tools for tumour tissue with ouruPathenterprise software.Open digital ecosystems connect innovators,from start-ups to technology leaders,to give lab professionals,clinici
189、ans,researchers and patients faster access to a wider range of innovation.This further advances our personalised healthcare solutions.Over time,the thousands of datapoints patients create throughout their journey will help identify changes in their health and enable tracking of similar patient group
190、s across institutions and geographies.Through artificial intelligence(AI)and machine learning,this will eventuallyallow for comparison of outcomes as wellas predictivemeasures.Moreover,we are carefully assessing the diversity of patient populations in all our diagnostics clinical trials,demonstratin
191、g our commitment to developing solutions that help to improve outcomes for patients around the world.For example,our Diagnostics Division is contributing in a very meaningful way to the Roche-wide Africa Genomics Program(AGP).In Diabetes Care,we are advancing our integrated Personalised Diabetes Man
192、agement(iPDM)strategy.We successfully deployed the Customer Population Insights Dashboard to streamline the data management process and enable healthcare professionals,administrators and payers to view population level trends.In time for the 10th anniversary of mySugr,the patient-centric interface a
193、t the core of our open ecosystem,we introduced extended functionalities and expanded smartphone compatibility for the mySugr Pump Control.Integrated solutions to improve outcomes50Active out-licensing agreements190Active in-licensing agreements300COVID-19 tests enabledper month67 millioncobas 6800/8
194、800 systems installed2079(since inception)Tests conducted with Roche Diagnostics products29 billionCOVID-19 key launches in 2022NameLaunch dateApprovalIndication/Disease,etc.System/PlatformCOVID-19 variant tests16 MarchResearch use onlySARS-CoV-2 B.1.1.529 variant,Omicron subvariants BA.1,BA.1.1,BA.
195、2,BA.2.2,BA.3 and Deltacobas 6800/8800LightCyclercobas z 480(depending on test)cobas SARS-CoV-2 Duo test15 JuneFDA Emergency Use Authorization SARS-CoV-2 RNA in nasal and nasopharyngeal swabspecimenscobas 6800/8800Elecsys IGRA SARS-CoV-2 test15 AugustCE MarkSupports understanding of immune response
196、toSARS-CoV-2 infection and vaccinationcobas e 411,e601/602,e402 and e801 analysersSARS-CoV-2 Rapid Antigen Test 2.01SARS-CoV-2 Rapid Antigen Test 2.0 Nasal2SARS-CoV-2 Antigen Self Test Nasal312 OctoberCE MarkSARS-CoV-2 tests delivering reliable results in asfew as 15minutesNo instrument neededcobas
197、SARS-CoV-2 Qualitative test 24 OctoberFDACOVID-19 PCR test performed on high-throughput platformcobas 6800/8800Diagnostics facts 2022Diagnostics|Roche 51Cancer key launches in 2022NameLaunch dateApprovalIndication/Disease,etc.System/Platformcobas HPV test with self-sampling solution16 JuneCE MarkSel
198、f-sampling for human papillomavirus(HPV)screening to prevent cervical cancercobas molecular instrumentsVENTANA DP 60028 JuneCE MarkCreates high-resolution digital images of stained tissue samples to help diagnose cancerSlide scanner as part of Digital Pathology portfolioBenchMark ULTRA PLUS28 JuneCE
199、 Mark and globalFully automated tissue-staining processNew systemVENTANA MMR RxDx Panel11 AugustFDA label expansionCompanion diagnostic for solid tumours treated with Mercks immunotherapy KeytrudaBenchMark ULTRADigital LightCycler System23 August15 countries worldwide,CE-marked with FDA 510(k)exempt
200、 statusNext-generation digital PCR system to help clinical researchers better understand the nature of a patients cancer,genetic disease or infectionNew systemPATHWAY anti-HER2 (4B5)test4 OctoberFDA Companion diagnostic for the assessment of HER2 low status in metastatic breast cancer patientsBenchM
201、ark ULTRA IHC/ISH slide-staining instrumentPRAME(EPR20330)Antibody11 Octobern/aEvaluates PRAME protein expression from patients with suspected melanomaBenchMark ULTRA IHC/ISH instrumentsVENTANA FOLR1(FOLR1-2.1)RxDx Assay14 NovemberFDAFirst immunohistochemistry companion diagnostic to aid in identify
202、ing epithelial ovarian cancer patients eligible for targeted treatment with Elahere(ImmunoGen)BenchMark ULTRAPoint of Care1 new testMolecular Lab2 new platforms 2 new tests 1 otherCore Lab4 new platforms 12 new tests 1 new digital solutionRoche Information Solutions4 new digital solutionsPathology L
203、ab1 new platform 9 new tests 3 new digital solutions1 otherDiagnostics key launches 20227249 new platformstestsdigital solutionsDiabetes Care1 new digital solution52Other key launches in 2022NameLaunch dateApprovalIndication/Disease,etc.System/Platformcobas infinity edge11 JanuaryRolling launches in
204、 selected marketsCloud-based platform connecting patient test results,medical records and third-party applicationsThree modules:unite,scribe and smartcobas pulse12 JanuaryCE MarkBlood glucose management solution with mobile digital health capabilitiesHandheld blood glucose management deviceFloodligh
205、t12 JanuaryMDR certificationA smartphone app that enables data-driven decision-making for patients with multiple sclerosisSmartphonemySugr Pump Control25 AprilLaunched in selected marketsAllows diabetes patients to import temporary basal rates from their Accu-Chek Insight insulin pump to themySugr a
206、ppAccu-Chek Insight insulin pumpThree LightMix Modular virus kits(quantitative PCR tests)25 MayAvailable for research use in majority of countries worldwideMpox virus detectionLightCycler 480 II instrument or cobas z480 analyzerElecsys HCV Duo immunoassay18 JulyCE MarkSimultaneous and independent de
207、termination of the hepatitis C virus antigen and antibody status from a single human plasma or serum samplecobas e 801 and cobas e 402 immunoassay analysersElecsys Amyloid Plasma Panel19 JulyFDA Breakthrough Device DesignationDetects and measures Alzheimers disease biomarkers in blood plasmaElecsys
208、technologycobas pure integrated solutions19 SeptemberFDANext generation of innovation in the cobas family ofSerum Work Area solutionscobas purecobas MPXV16 NovemberFDA Emergency Use AuthorizationPCR test for qualitative detection of DNA from mpoxviruscobas 6800/8800Elecsys AD CSF assays8 DecemberFDA
209、Cerebrospinal fluid assays supporting more accurate and timely diagnosiscobas fully automated immunoassay analysersDiagnostics|Roche 5354PharmaceuticalsWe are proof that scientific innovation leads to productsthat truly save and improve patients lives.Focusing on oncology,immunology,ophthalmology,in
210、fectious diseases,neuroscience,metabolic and rarediseases,we translate excellence in science intoeffectivemedicines for patients.Frankline received treatment for her breast cancer through the first national access programme in Kenya.Theprogramme is an important step for Kenyan women with breast canc
211、er to access standard-of-care treatment.Breast cancer patientKenya,East AfricaFrankline AkinyiOtienoRicky is part of the team working to improve how patients receive healthcare and access medicine.His work has resulted in a new and transformative way to provide direct-to-patient treatment delivery a
212、nd home care services.Global Value Stream Strategy Lead Basel,SwitzerlandRicky AlasPharmaceuticals|Roche 57Frankline AkinyiOtieno58Overcoming challenges to accessing breast cancer treatment in KenyaAs a peer educator at the Centre for Health Solutions facility in Ukwala town,Kenya,Frankline Akinyi O
213、tieno works with women to educate and support them on a range of health issues.For the past six years she has been visiting women in the community to speak about reproductive and sexualhealth,including topics such as sexually transmitted infections and family planning.Frankline also educates women o
214、n how to perform breast self-examinations and encourages them to go for cervical cancer screenings.While her role requires extensive knowledge on these topics,Frankline had already learned long agothe importance of self-examinations and screening from observing posters at the hospital that she used
215、to visit frequently for her asthma.Routinely performing breast self-examinations proved to be acritically important practice in her own life when she found a lump herself.Frankline immediately consulted her doctor and wasreferred to a specialist at Jaramogi Oginga Odinga Teaching and Referral Hospit
216、al(JOOTRH)for further investigation.Following an ultrasound,mammogram and biopsy,in May 2021 Frankline wastold that she had breast cancer.Exploring alternative treatment options“It was a huge shock hearing that I had breast cancer,”she recalls.“I really wasnt expecting it because I was breastfeeding
217、 at the time,and prior to this,the tests I had done indicated that thelump was normal.I was told it would subside withtime.”Upon hearing her diagnosis,Frankline was hesitant to follow the recommended hospital treatment because she was afraid of the potential effects on her well-being.She also faced
218、stigma from family,friends and colleagues,which amplified her concerns.“They told me that cancer is expensive and that people dont survive chemotherapy.”Her family had a difficult time accepting the cancerdiagnosis and they were also concerned about the medical treatment,insisting that she first try
219、 herbal medicine.Although Frankline had reservations,she tried this option for two months.Ultimately the herbal medicine didnt work,so Frankline returned to JOOTRH to proceed with the recommended treatment plan from the doctors.Confronted by access challenges Frankline underwent a mastectomy,followe
220、d by eight cycles of chemotherapy.The impact on her lifewas indeed significant.“It was not an easy journey for me,”she says.“I had never had surgery before and I really wasnt comfortable.I got quite sick from the chemotherapy and my arm became constrained after the surgery.I couldnt lift heavy objec
221、ts,hang clothes to dry on the line,or sleep on my right side.People started seeing me differently and my self-esteem suffered as a result.”Following the surgery and chemotherapy,Franklinewas to continue with hormonal treatment.Her treatments had been covered by the National Health Insurance Fund(NHI
222、F)up until this point,butnow she was faced with a difficult decision.“TheNHIF covered the mastectomy and chemotherapy,as well as the first four hormonal treatments,but after that I needed to pay for the remaining 14treatments,”Frankline explains.“Icouldnt afford it and I didnt know what to do next.I
223、 was stuck,so I had to stop my treatment fortwo months while I weighed myoptions.”Pharmaceuticals|Roche 59Soon Frankline had her answer.In June 2022,the Ministry of Health in Kenya,the NHIF and Roche announced a partnership to make breast cancer treatment available to all NHIF members in Kenya.This
224、was the first national access programme for cancer medicines in Kenya,and an important step to ease the financial burden of Kenyan women with breast cancer and ensure they have access to standard-of-care treatment.Breast cancer is the most commonly diagnosed cancer in Kenya,with 6,000cases diagnosed
225、 each year and 2,500breast cancer-related deaths.1 Through this partnership,Roche is helping strengthen the diagnostic ecosystem for breast cancer screening and early diagnosis of patients,aswell as improve the referral pathways to treatment centres so that women can get the treatment they need in a
226、 timely manner.For Frankline,this welcome news meant that she didnot have to worry about paying out of pocket and that she could continue with her treatment.“This made it easier for me because I could now getmy full treatment covered.”A bright futureWhile Frankline is thankful that she was able to a
227、ccess her treatment,she also recognises the importance of her own knowledge and the impact of screening.“The self-examination saved my life,”she says.“I want to advocate for all women to get screened;the earlier the better so you can get the right diagnosis and treatment.Cancer doesnt have to be a d
228、eath sentence as long as you get thediagnosis early enough.”Today,Frankline is responding well to the treatmentand she is optimistic about what her future holds.“Ibelieve that all my dreams for the future will go as planned and that I will live a normallife,”she says.A big part of that future is hel
229、ping her son realisehisown dreams.“My son is my comfort;whenI am sick,he tells me all will be well.So Iwantthe very best for him,”says Frankline.“Hewants to be a pilotwhen he grows up,and I hope to help him with his education.I know I will live and seethat happen,andhe can fly me all aroundtheworld.
230、”“I want to advocate for all women to get screened;the earlier the better so you can getthe right diagnosis and treatment.”1 Cancer on the Global Stage:Incidence and Cancer-Related Mortality in Kenya.World Health Organization Region:Africa,The ASCO Post60Like many women with breast cancer in Kenya,F
231、rankline faced financial challenges that prevented her from getting the medicine she needed.A new collaboration between the Ministry of Health in Kenya,the NHIF and Roche has made breast cancer treatment available,making it easier and more accessible for women like Frankline to receive standard-of-c
232、are treatment.Now Frankline isdoing well and looks forward to a bright future with her son.Pharmaceuticals|Roche 61Improving access to treatment for patients fromthe comfort of their own homeWhen Ricky Alas worked as a consultant in digital innovation and corporate venture building in San Francisco,
233、he was exposed to a number of industries,ranging from financial services to consumer packaged goods.But after ten years,Ricky was ready for a change.Of all the industries hed worked in,he was most drawn to healthcare.He wanted to be part of an organisation that had a direct and tangible impact on im
234、proving peoples lives,so in 2019 he joined Genentech as a Digital Transformation Lead in Global Supply Chain.Shortly after settling in,Ricky was given the opportunity to work on a project called Integrated Direct Delivery to Patients,or ID2P,where the value for patients was clear.ID2P stemmed from a
235、n exercise to answer the question:“What would the healthcare system look like if it was designed around what patients and their family members needed and wanted so they could make the most oftheir life?”The initial thinking was to improve some of the processes in healthcare delivery to better suppor
236、t patients and caregivers,and simplify how they get treatments.The key solution pointed to direct-to-patient delivery and home care services,and thus ID2P was born.If successful,the project would improve the quality of healthcare service to patients and family members,alleviate hospital and clinic b
237、urden by reducing the number of in-person patient visits,and improve outcomes for patients through greater convenience and potentially better treatment adherence.Meeting patients where they are While home delivery of consumer goods from pizza to appliances is part of our everyday life,home delivery
238、of specialty medicine is still uncommon.And yet it can make a significant improvement in a patients quality of life while also having the potential to save healthcare costs through more efficient processes and delivery of treatment.Ricky and the global ID2P team were initially taskedwith finding a w
239、ay to make home delivery of Evrysdi,an oral treatment for spinal muscular atrophy(SMA),a reality no small feat considering nothing like this existed for a medicine that would typically have to be picked up from a specialty treatment centre,which could be hours from a patients home.They set out to cr
240、eate a solution that was“desirable to patients and the ecosystem,feasible and viable,”according to Ricky.“It felt almost like a start-up.There are very few times you get to build a new business in an established company,andfor Roche to give us that opportunity was amazing.”“If you think about Roches
241、 ambition to provide more benefit to patients at less cost to society,ID2P does exactly that,”says Ricky.“Im proud to work for an organisation that not only has such ambitious goals,but also comes up with new and creative ideas to achieve them.We dont always know what will work but we are always try
242、ing to find ways to improve peoples lives.”When the programme was launched in 2020,the interest from offices around the world to participate was overwhelmingly positive.However,the road ahead was challenging as the team forged new paths in every direction from legal and regulatory requirements to su
243、pply and logistics solutions while also taking into account stakeholder needs and preferences.“It was such an unknown and 62Ricky AlasPharmaceuticals|Roche 63Ricky and the ID2P team work with colleagues around the globe to design,develop and implement tailored programmes that enable delivery of trea
244、tments directly to patients in their own homes.This convenient solution can save countless hours of travel time to specialty hospitals which,for patients with rare and chronic conditions like SMA or haemophilia and their caregivers,can be life-changing.64unconstrained space,”recalls Ricky.“There was
245、 noroad map or industry barometer for success.We were figuring it out as we went and when we hit roadblocks,they were amplified because we only had ourselves to look at.”Despite the challenges,ID2P has seen significant growth,increasing from aninitial launch of nine pilot programmes in its first yea
246、r to more than 40programmes in Roche affiliates across the globe in2022.What has made ID2P so successful?“The people,”Ricky says without hesitation.“Those who lead the project in their respective countries and were involved in the day-to-day work,who overcame constraints every step of the way.This p
247、roject wouldnt be possible without their passion,initiative and drive towards a single goal:addressing the unmet needs of ourpatients.”Collaboration without bordersThe local teams came together to design and deploysolutions in collaboration with ecosystem partners,with the power and resources of the
248、 full ID2P network behind them.Ricky feels fortunate that he gets to work with colleagues in almost every country.“You have all these diverse perspectives and cross-functional backgrounds at every level of the project working together and trying to help each other find solutions to these challenges,
249、”heexplains.While its clear that Ricky is passionate about making a difference for people and that ID2P has had a significant impact on improving patients lives,what Ricky enjoys most about the project is the relationships hes formed.“I feel like Ive genuinely made friends,even though Ive met very f
250、ew of them in person.I think that comes from getting to do meaningful work in a cool way with dedicated people.”Trailblazing new paths to accessID2P shows no sign of slowing down,as more affiliates continue joining the project and creating their own fit-for-purpose direct-to-patient and out-of-hospi
251、tal solutions.In fact,Ricky is hopeful that it could serve as a future capability for severalof Roches pipeline products.“I dont see a world in which we can talk about ID2P as a project for much longer.It will just be our way of demonstrating the full value of our medicines for patients and ecosyste
252、ms.”Ricky thinks Roche can play a role in helping ecosystems adapt and establish the necessary capabilities to enhance access and firmly place patients at the heart of it all.“I believe that the evolution of healthcare is going to continue towards a much more patient-centric realm,”he says.“ID2P is
253、just the beginning,and theres so much more we can do to trigger that transformation.”Having recently relocated to Basel with his wife and two young children,Ricky is excited to continue playing his part in ID2P and is excited to meet some of the friends hes made along the way.“I believe that the evo
254、lution of healthcare is going to continue towards a much more patient-centric realm.”Pharmaceuticals|Roche 65A clear commitment to innovationOur commitment to innovation has never been clearer and in the past year we made major investments in both research and development.Our unique combination of a
255、utonomous and independent research organisations together with our investment in a strong network of more than 250 external partner organisations globally drives pioneering scientific and technological breakthroughs across healthcare.In 2022,we launched Vabysmo,the first bispecific antibody approved
256、 for the eye.It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2(Ang-2)and vascular endothelial growth factor-A(VEGF-A).Vabysmo is approved in more than 50 countries around the world,including the United States,Ja
257、pan,the UnitedKingdom and the European Union for people living with neovascular or wet age-related macular degeneration and diabetic macular oedema.Review by other regulatory authorities isongoing.We continue to pioneer new ways totreatvision-threatening eye diseases.The European Commission approved
258、 a Polivy combination in previously untreated diffuse large B-cell lymphoma(DLBCL)and our first-in-class bispecific antibody Lunsumio for the treatment of relapsed or refractory follicular lymphoma.Lunsumio represents a new type of immunotherapy that is a chemotherapy-free and fixed-duration treatme
259、nt option with the potential to provide durable remissions and offer a significant period of time without treatment,following initial therapy.The Polivy combination is the first treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival that is no
260、w approved in the EU for patients with previously untreated DLBCL.Although the phase III GRADUATE I and II trials did not meet their primary endpoints of slowing clinical decline in people with early Alzheimers disease,Roche remains committed to this disease,one of the most complex neurological diso
261、rders and major public health challenges.We are continuing to develop and deliver tests to enable early and accurate diagnosis,and have a pipeline of investigational medicines for different targets,types and stages of the disease.The power of partnershipsFacilitating patient access to quality medici
262、nes is at the heart of our business.To meet the rising global demand for high-quality and accessible healthcare services,we have further integrated comprehensive and actionable plans into our work and enhanced our patient partnerships worldwide.In 2022,we entered a first partnership with a holistica
263、pproach to improving population health with the International Federation of Red Cross and Red Crescent Societies(IFRC).This collaboration will help us to unlock access to previously underserved populations worldwide and will strengthen our commitment to meet the needs of patients no matter who they
264、areor wheretheylive.Advancing inclusive researchWe are deeply committed to addressing barriers to clinical trial participation and advancing inclusive research.We believe that improving health outcomes for all patients is core to our mission,and we are committed to being industry leaders in offering
265、 patients with serious and life-threatening diseases achance to receive investigational medicines.We are aiming to continuously evolve our processes to improve accessibility,convenience and ultimately adherence,leading to better outcomes for patients and a reduced burden for caregivers.In order to m
266、eet the unique requirements in each country,global and country colleagues are working closely together with external stakeholders to go the extra mile for patients.66Pharmaceuticals clinical pipelinePhase IPhase IIIPhase IIRegistrationOncologyInflammation/ImmunologyInfectious diseasesMetabolicsNeuro
267、scienceOphthalmologyOthers5327672Our pipeline of 87 new molecular entities covers a broad range of diseases,and highly innovative technologies are applied to create and produce the activemolecules.Pharmaceuticals|Roche 67Agreements derived from existing alliances 16PHC agreements13Product
268、,technology or discovery licence agreements16Product out-licensing agreements and divestments5Number of new partnerships in 2022Acquisition1Research and discovery collaborations1162new partnerships6827major approvalsUS 9Europe 5Major approvals in 2022China4 Lunsumio Follicular lymphoma,third-line tr
269、eatment Polivy Diffuse large B-cell lymphoma,first-line treatment Tecentriq Non-small cell lung cancer,adjuvant therapy Vabysmo Diabetic macular oedema Vabysmo Neovascular or wet age-related macular degeneration Actemra/RoActemra Rheumatoid arthritis,subcutaneous Rozlytrek NTRK-positive solid tumour
270、s Rozlytrek ROS1-positive non-small cell lung cancer Tecentriq Non-small cell lung cancer,adjuvant therapy Actemra/RoActemra COVID-19 pneumonia Actemra/RoActemra Giant cell arteritis,intravenous Cotellic Histiocytosis Lunsumio Follicular lymphoma,third-line treatment Tecentriq Alveolar soft part sar
271、coma Evrysdi Spinal muscular atrophy,presymptomatic paediatric 100,000 patient profiles Partnership with Epic1 breakthrough device designation1 million clinical reportsFoundation Medicine milestones 2022More than 100,000 linked patient profiles in the Foundation Medicine and Flatiron Health Clinico-
272、Genomic Database(CGDB)First customer as part of partnership with Epics electronic medical record(EMR)system went liveBreakthrough device designation received for FoundationOne Tracker,a circulating tumour DNA(ctDNA)detection and molecular monitoring assayOne million reports delivered from the Founda
273、tionOne portfolio of comprehensive genomic profiling(CGP)testsNew molecular profilingInternational expansionMore than 100,000 linked patient profiles in the Foundation Medicine and Flatiron Health Clinico-Genomic Database(CGDB)New molecular profiling integration with Caris Life Sciences and Foundati
274、on Medicine International expansion focused on transforming global oncology research and care with subsidiaries in Japan,Germany and the United KingdomFlatiron Health milestones 2022100,000 patient profiles Fourteen accepted Flatiron-authored poster discussions and presentations showcasing Flatirons
275、 scientific leadership at key industry conferences14 Flatiron-authored poster discussions23 Flatiron-authored publicationsTwenty-three Flatiron-authored papers were accepted and published in peer-reviewed journalsPersonalised healthcare|Roche 8384 Access to healthcareWorking in collaboration with gl
276、obal and local stakeholders,we support governments efforts to build strong and resilient healthcare systems,particularly for people in low-and lower-middle-income countries.Every countrys healthcare system is unique,so we work closely with partners to develop and deliver tailored solutions.UN SDGsMa
277、terial topics Long-term mindset Availability of healthcareAt a newly opened cancer treatment centre in Ghana,DrNgyedu is focused on addressing the challenges cancerpatients face during their journey.Heisgratefulforthe power of partnerships thatdirectlybenefitpatients.Chief Executive Officer,Cape Coa
278、st Teaching HospitalCape Coast,GhanaDr Eric NgyeduDr Altamirano has played a key role in advising the Ministry of Health in Chile in its evolution towards HPV testing for cervical cancer screening a critical prevention strategy and important step towards eradicating the disease in the country.Gynaec
279、ologic OncologistSantiago,ChileDr Roberto AltamiranoAccess to healthcare|Roche 87Dr Eric Ngyedu88Breaking down barriers to cancer care in GhanaThroughout DrEric Ngyedus career,he has spent a great deal of his time and effort on improving the health of people in Ghana.After training to become an oral
280、 and maxillofacial surgeon in Santa Clara,Cuba,DrNgyedu returned home to Ghana in 2007 and soon found that he could make the biggest impact on the community by delivering and improving care for all Ghanaians.Today,Dr Ngyedu is the Chief Executive Officer of the Cape Coast Teaching Hospital(CCTH)on t
281、he west coast of Ghana.The hospital is a world-class leader in tertiary healthcare as well as medical research and serves as a training ground for undergraduate and postgraduate training for medical and other health professionals.As of 2021,the hospital is also the site of a new cancer treatment cen
282、tre.Cancer is one of the most significantpublic health challenges in Ghana,with more than 24,000new cases diagnosed in 2020 and more than15,800people dying from the disease.1“Ghanaians face numerous challenges during theirpatient journey,including health,mental,social and financial hurdles,”explains
283、 DrNgyedu.“We have limited infrastructure,limited access to comprehensive treatment centres and limited access to affordable cancer medicines.All of those challenges put together mean patients are experiencing a harrowing journey.”Addressing a significant public health challengeThanks to a partnersh
284、ip between Roche and the government of Ghana,work has begun to develop infrastructure to deliver cancer care at key hospitals across the country.CCTH is one of three new treatment centres that have been opened across the country through this partnership.It is already starting to address geographic a
285、ccess barriers to quality cancer care,support capacity building and training for healthcare workers,and support awareness creation in communities around the country.“Before our cancer centre opened in 2021,only two public hospitals in Ghana were mandated to provide cancer services and facilities and
286、 were often overburdened,leading to delays in patient access to specialised care,”says DrNgyedu.“This does not bode well for managing outcomes and worsens patients prognosis.The financial hardships presented by long travels also worsen the plight of patients.We knew it was crucial to curb these chal
287、lenges by establishing this new centre to service patients within and outside the region.”The centre provides not only the infrastructure and space for oncology patients to be treated,but also the treatments themselves.An oncology pharmacy and cold room were established as well to support the provis
288、ion of quality medicines and reagents used for diagnosis and treatment.A unique partnershipRoche has long been working to improve oncology care in Ghana,and DrNgyedu is grateful for partnerships like this one that directly benefits patients.“Our partnership with Roche is a unique one.It is 100%patie
289、nt-centred.Its not about products;its about supporting patient care and breaking down barriers that cancer patients face,”he says.“The private sector has a critical role to play in increasing access to care for the people of Ghana.We need partnerships like this to move the needle and make meaningful
290、 change.”1 International Agency for Research on Cancer,World Health Organization,Ghana Fact SheetAccess to healthcare|Roche 89One meaningful change that this partnership has brought about is the increased screening and treatment for breast cancer patients.“This year for breast cancer awareness month
291、 in October,we were able to screen over 4,000people for breast cancer.Because of the support we have received from Roche in providing the infrastructure,we were able to do this at no cost to the patients,”says DrNgyedu.“Additionally,Roche has been working with the government to enable public funding
292、 of keycancer treatments.This is a testament to the impact these partnerships can have.”A sustainable futureAlthough the tides are beginning to turn for patients in Ghana,there are still many opportunities to pave the way for increased access to care in the future.“Leveraging technology to provide c
293、are for cancer patients is critical,”reflects DrNgyedu.“Because a large portion of the population lives in remote areas,we need to find a way to provide care throughtelemedicine.It is absolutely possible to care for cancer patients from a distance but we need the technology in place to do so.Partner
294、ships with the private sector have helped us get where we are today and they will continue to do so in thefuture aswe look to the role technology canplay.”Roche has made a long-term commitment to Ghanaand the African continent,and will continue to invest in strengthening health systems and collabora
295、ting with partners to implement innovative solutions that are tailored to the specific needs of patients in the region.For DrNgyedu,this brings hope for the future of healthcare in Ghana.“When we all have the patient at the centre of what we do,we willalways do the right thing.”“Our partnership with
296、 Roche is a unique one.It is 100%patient-centred.Its not about products;its about supporting patient care and breaking down barriers.”90Cape Coast Teaching Hospital is home to a new cancer treatment centre that has increased access to screening and treatment for patients in Ghana.Dr Ngyedu believes
297、cancer care will continue toevolve thanks to new technologies and partnerships with the private sector.Access to healthcare|Roche 91Leading a critical evolution for cervical cancer prevention in ChileThroughout his life,Dr Roberto Altamirano understood the importance of good health and was passionat
298、e about helping people and making a difference.It was this passion that led him to medicine,and specifically gynaecologic oncology.“I wanted to be a surgeon but,more than that,Iwanted to see and treat each patient as a whole person.My main goal is to help others and have animpact onthe community.”Re
299、cently Dr Altamirano has made significant progress towards this goal by playing a role in changing the health system and improving cervicalcancer screening in Chile.A long-standing process in screeningSince 1987,Chile has had a national cervical cancer screening programme where the Pap test is used
300、as the standard to identify women at risk.While the programme has reduced mortality rates over time,women continue to be diagnosed with this preventable disease,suggesting that it hasnt been as effective with early detection as it could be.“In almost 50%of cervical cancer cases,womenhavent done any
301、kind of screening test.Thisis a missed opportunity for prevention,”explainsDrAltamirano.Despite being almost 100%preventable with vaccination,screening and treatment,cervical cancer claims the lives of more than 34,000women every year,making it one of the leading causes of cancer deaths in women.1 H
302、umanpapillomavirus(HPV)is the known cause of nearly all casesof cervical cancer,so finding and treating pre-cancerous disease before cancer develops isanimportant preventionstrategy.2An evolution towards improved prevention The cervical cancer guidelines have evolved overthe years and a critical mil
303、estone was achievedin 2019.The Ministry of Health in Chile introduced a pilot project to implement HPV testingin 14 of its 26health services.“We have a good health systembut we needed to make an upgrade becausethe Pap test has its limitations,”says DrAltamirano.As an advisor to the Ministry,he has b
304、een advocating for HPV testing for many years.“Ive been putting this forward since 2015,”he explains.“I started working with my mentors on how to improve the health system because we had a shared vision to help as many people as possible.The best way todo that was to change how we conduct screening
305、toenable better prevention,so I was persistent in the need for HPV testing.”Chile,among other countries,is moving towards a screening programme where HPV is the primary test for eligible women,3 in line with World Health Organization(WHO)recommendations.4 This strategy aims to better identify those
306、who are at riskfor disease in order to prevent invasive cancer from developing.Overcoming barriers to adoption When the programme was first introduced,severalbarriers prevented some women from beingscreened.Says Dr Altamirano:“Our biggest problem is that a lot of women dont get tested because they t
307、hink they dont need it,dont have time or think that its going to hurt,so the opportunity for screening is often missed.”1 Cervical cancer fact sheet,World Health Organization|2 Cervical cancer screening for individuals at average risk:2020 guideline update,American Cancer Society|3 Implementacin del
308、 diagnstico molecular del VPH:experiencia chilena en curso.Revista Mdica de Chile|4 Global strategy to accelerate the elimination of cervical cancer as a public health problem,World Health Organization92Dr Roberto AltamiranoAccess to healthcare|Roche 93Dr Roberto Altamirano was a key advocate for a
309、pilot programme in Chile that emphasises HPV testing as the primary screening method for eligible women an important strategy to prevent cervical cancer.He continues on his mission to raise awareness and education about HPV and the importance of cervical cancer screening so women have the power of k
310、nowledge to take care ofthemselves.94“We needed to increase awareness about HPV and teach patients about the importance of prevention,”he says.“Education was critical not only for patients,but also for healthcare professionals because they werent comfortable talking about HPV and were so accustomed
311、to the Pap test.”In addition to providing the HPV test to the health services in the pilot programme,Roche worked withpartners to train the primary healthcare providers who collect samples,and supported education programmes to increase awareness about HPV and the importance of screening and preventi
312、on.DrAltamirano believes this was crucial to help bring healthcare professionals on board withthe new screening method,explaining that“those who went through the teaching programme and learned how to perform the HPV test adapted really well tothechange.”He has also seen the impact among patients.“Wi
313、th all the education were doing,women have now started asking for the test.People are becoming more involved,seeking information and starting toknow about HPV.”Chiles national ambitionToday,around 250,000 women have been screened through the programme,and the Ministry of Health plans to expand HPV t
314、esting to all health services in Chile with the ultimate goal to achieve national access for all eligible women.Dr Altamirano thinks that with HPV testing in place,more women can be reached.“The HPV test can be done every five years,which means we dont have to keep screening the same women every yea
315、r.We can be relatively confident that a woman with a negative HPV test has a low risk of developing cervical cancer,so we can focus on ensuring other womenare screened to identify those who are at ahigher risk.”He also believes the programme is a critical step to help the country meet the WHOs goal
316、of eradicating cervical cancer within the next century.“Im a dreamer and I try to stay positive because I think its going to work,”he says.“As with any other change,we need time.But if we keep insisting everyday that this is the right thing to do,we can achieve this goal and eliminate the disease.”A
317、n ongoing thirst for knowledgeToday,Dr Altamirano is entrenched in the Chilean health system.As a self-proclaimed multi-tasker,heis a practising gynaecologic oncologist in public and private healthcare,he is a member of the Chilean Society of Obstetrics and Gynaecology,and an advisor to the Ministry
318、 of Health,recently expanding his knowledge in this area by earning a masters in health administration.He is also an Assistant Professor of Obstetrics and Gynaecology at the University of Chile.But above all,he remains committed to his goal of helping others.“Through the years and with myexperience,
319、I am most passionate about educating patients and the next generation of gynaecologic oncologists.I believe I can do the bestby giving people the power of knowledge totake care of themselves.”“I believe I can do the best by giving people the power of knowledge to take care ofthemselves.”Access to he
320、althcare|Roche 95The power of partnershipsAt Roche we know that our diagnostics and medicines can only positively impact lives ifthey reach the people who need them.Every country has its own unique challenges when it comes to accessing healthcare,something whichvaries dramatically from country to co
321、untry.Funding,infrastructure,healthcare capacity and disease awareness all play a role,which is why wefirmly believe in the need to take a holistic andcollaborative approach to address potential barriers.These challenges are simply too complex for any single party to solve alone.Increasing access to
322、 diagnostics around theworldOver the past decade our public-private partnerships have strengthened laboratory systemsin African nations highly impacted by HIV/AIDS,built the institutional capacity of regionalandnational partners and improved quality in diagnostic services across the continent.Togeth
323、er our efforts have improved millions of lives.For example,we have worked in partnership with the US Presidents Emergency Plan for AIDS Relief(PEPFAR)to scale up HIV viral load testing andearly infant diagnosis.In May 2022,we entereda new partnership with the Global Fund to build local capacity to t
324、ackle fundamental infrastructure challenges forgenerating and delivering diagnosticresults andmanaging healthcare waste.Addressing diabetes access barriers and disparities worldwidePublic-private partnerships are critical to developing sustainable access initiatives and this is something that we hav
325、e seen with diabetes.Together with our partners,Roche plays its part in addressing diabetes access barriers and disparities worldwide,such as through the Changing Diabetes in Children programme run by Roche Diabetes Care,Novo Nordisk and other global and local partners.The public-private partnership
326、 has reached more than 38,000children in over 25countries since 2009,with Tunisia and Vietnam joining the project in 2022.Initiatives to increase access to medicines inlow-and lower-middle-income countriesIn 2022,we were also delighted to renew our long-standing partnership with the World Federation
327、 of Hemophilia.Through this partnership more than 1,000patients with haemophiliaA in low-and lower-middle-income countries are being reached through aid programmes.In addition,hundreds of healthcare professionals are being trained,and testing capacity has been enabled and expanded.Additionally,we we
328、re proud to become a member ofthe Access to Oncology Medicines(ATOM)Coalition,a new global partnership led by the Unionfor International Cancer Control,to increase access to quality-assured essential cancer medicines in low-and lower-middle-income countries and to help countries develop the capacity
329、 for their proper use,including training and diagnostics.This partnership will complement our existing goal to doublethe number of patients receiving our innovative therapies in low-and lower-middle-income countries by the end of 2026.The goal aims to overcome the many barriers patients face in low-
330、income countries,such as a lackof infrastructure as well aseconomic pressuresandregulatory challenges.This is just a small summary of the initiatives that we are working on to expand access to healthcare around the world.Partnerships sit at the very heartof our access work,and in 2023 we will contin
331、ue to work closely with public,private and non-governmental organisations to broaden accessto healthcare and to our diagnostics andmedicines.96Around 360,000 women13 citiesMore than 38,000 childrenRoche ranked 10th Over 8 million HIV-positive patientsin low-and lower-middle-income countries were scr
332、eened for cervical cancer in 2022 with the support of Roches Global Access Program,more than double compared to 2021We continue to work with City Cancer Challenge,who are active in 13 cities worldwide reaching an estimated 59.6million peoplein over 25 countries were reached through the Changing Diab
333、etes in Children programme,a partnership with Novo Nordisk,since its launch in 2009worldwide in the Access to Medicine Indexwere able to have their viral load monitored through the Global Access Program to check fortreatment efficacyOver 3.2 million peopleon Roche patient support programmes,a14%increase from 202129 billion tests52%more patients100,000 peopleconducted with Roche Diagnosticsproducts